Synthesis and evaluation of HIF-1α inhibitory activities of novel panaxadiol derivatives. 2020

Da-Yuan Wang, and Yan-Wei Li, and Lin-Hao Zhang, and Li-Yan Lv, and Yu-Qing Zhao, and Xue-Jun Jin, and Hu-Ri Piao
Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji 133002 China.

Hypoxia-inducible factor 1α (HIF-1α) is a known regulator of tumor cell proliferation, migration, and angiogenesis. The presence of a high concentration of HIF-1α is positively correlated with the severity of cancer. Therefore, the inhibition of this pathway represents an important therapeutic target for the treatment of various types of cancer. Here, we designed and synthesized 30 panaxadiol (PD) derivatives and evaluated their inhibitory activities against HIF-1α transcription. Of these, compound 3l exhibited the most promising inhibitory activity (IC50 = 3.7 µM) and showed significantly decreased cytotoxicity compared with PD. Compound 9e exhibited the strongest cytotoxic effect and may be considered for further preclinical development.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015533 Transcriptional Activation Processes that stimulate the GENETIC TRANSCRIPTION of a gene or set of genes. Gene Activation,Genetic Induction,Transactivation,Induction, Genetic,Trans-Activation, Genetic,Transcription Activation,Activation, Gene,Activation, Transcription,Activation, Transcriptional,Genetic Trans-Activation,Trans Activation, Genetic
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D051795 Hypoxia-Inducible Factor 1, alpha Subunit Hypoxia-inducible factor 1, alpha subunit is a basic helix-loop-helix transcription factor that is regulated by OXYGEN availability and is targeted for degradation by VHL TUMOR SUPPRESSOR PROTEIN. Hypoxia Inducible Factor 1, alpha Subunit
D036145 Ginsenosides Dammarane type triterpene saponins based mainly on the aglycones, protopanaxadiol and protopanaxatriol. Ginsenoside,Panaxosides,Sanchinosides

Related Publications

Da-Yuan Wang, and Yan-Wei Li, and Lin-Hao Zhang, and Li-Yan Lv, and Yu-Qing Zhao, and Xue-Jun Jin, and Hu-Ri Piao
June 2019, Bioorganic & medicinal chemistry letters,
Da-Yuan Wang, and Yan-Wei Li, and Lin-Hao Zhang, and Li-Yan Lv, and Yu-Qing Zhao, and Xue-Jun Jin, and Hu-Ri Piao
June 2024, Fitoterapia,
Da-Yuan Wang, and Yan-Wei Li, and Lin-Hao Zhang, and Li-Yan Lv, and Yu-Qing Zhao, and Xue-Jun Jin, and Hu-Ri Piao
April 2022, Bioorganic chemistry,
Da-Yuan Wang, and Yan-Wei Li, and Lin-Hao Zhang, and Li-Yan Lv, and Yu-Qing Zhao, and Xue-Jun Jin, and Hu-Ri Piao
August 2022, Chemistry & biodiversity,
Da-Yuan Wang, and Yan-Wei Li, and Lin-Hao Zhang, and Li-Yan Lv, and Yu-Qing Zhao, and Xue-Jun Jin, and Hu-Ri Piao
January 2020, Chemistry & biodiversity,
Da-Yuan Wang, and Yan-Wei Li, and Lin-Hao Zhang, and Li-Yan Lv, and Yu-Qing Zhao, and Xue-Jun Jin, and Hu-Ri Piao
June 2011, European journal of medicinal chemistry,
Da-Yuan Wang, and Yan-Wei Li, and Lin-Hao Zhang, and Li-Yan Lv, and Yu-Qing Zhao, and Xue-Jun Jin, and Hu-Ri Piao
December 2017, Bioorganic chemistry,
Da-Yuan Wang, and Yan-Wei Li, and Lin-Hao Zhang, and Li-Yan Lv, and Yu-Qing Zhao, and Xue-Jun Jin, and Hu-Ri Piao
September 2017, Bioorganic & medicinal chemistry letters,
Da-Yuan Wang, and Yan-Wei Li, and Lin-Hao Zhang, and Li-Yan Lv, and Yu-Qing Zhao, and Xue-Jun Jin, and Hu-Ri Piao
March 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Da-Yuan Wang, and Yan-Wei Li, and Lin-Hao Zhang, and Li-Yan Lv, and Yu-Qing Zhao, and Xue-Jun Jin, and Hu-Ri Piao
October 2003, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!